Table 4 One-way sensitivity analyses for sarcoma patients in France, all anthracycline doses
Description of analysis | No dexrazoxane | With dexrazoxane | Incremental costs € | Incremental QALYs | ICER € | ||
|---|---|---|---|---|---|---|---|
Total costs € | Total QALYs | Total costs € | Total QALYs | ||||
Base case | 12,102 | 19.78 | 12,549 | 20.35 | 447 | 0.57 | 791 |
Risk of CHF is based on French general population prevalence data multiplied with relative risks for childhood cancer survivors [15] | 18,047 | 15.22 | 15,437 | 17.61 | − 2609 | 2.39 | Dominant |
Risk of CHF is extrapolated with a linear function | 11,854 | 20.06 | 12,477 | 20.48 | 624 | 0.42 | 1493 |
Risk of death modelled with general population life tables multiplied by SMR for childhood cancer survivors [20] | 13,103 | 19.70 | 13,668 | 20.17 | 565 | 0.47 | 1214 |
Treatment effect modelled with Bayesian RR | 12,099 | 19.78 | 12,575 | 20.31 | 476 | 0.53 | 895 |
Utility data based on NYHA class [22] and not differentiated by age | 12,099 | 20.37 | 12,548 | 20.61 | 449 | 0.23 | 1922 |